Human CD229/SLAMF3 Antibody Summary
Lys48-Lys454
Accession # Q9HBG7
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD229/SLAMF3
CD229, also known as Ly9 and SLAMF3, is a 120 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family (1). Mature human CD229 consists of a 407 amino acid (aa) extracellular domain (ECD) with two Ig‑like V-set and two Ig‑like truncated C2-set domains. It also shows a 22 aa transmembrane segment, and a 179 aa cytoplasmic domain with two immunoreceptor tyrosine-based switch motifs ITSMs (2, 3). The ECD of human CD229 shares 57%‑59% aa sequence identity with mouse and rat CD229. Within the first two Ig‑like domains that are common to all SLAM proteins, human CD229 shares 24%‑39% aa sequence identity with human 2B4, BLAME, CD2F-10, CD84, CRACC, NTB-A, and SLAM. Alternate splicing generates two additional isoforms that lack the juxtamembrane Ig‑like domain or short cytoplasmic region (2). CD229 is expressed on T and B cells, thymocytes, and more weakly on NK cells (2‑6). Homophilic binding between CD229 molecules is mediated by the N-terminal Ig‑like domain (7). Human and mouse CD229 exhibit cross-species binding (7). Antigen stimulation of lymphocytes induces CD229 clustering to sites of T cell‑B cell contact (7). Two tyrosines in the cytoplasmic domain are required for association of CD229 with the adaptor proteins AP-2 (μ2 chain) and GRB-2 and both are required for CD229 internalization (8, 9). In addition, there are two ITSMs which mediate phosphorylation-dependent CD229 association with SAP and SHP-2 (10). These four tyrosine-containing motifs are intact in the described CD229 splice variants. CD229 knockout mice show minimally impaired immune responses, suggesting functional redundancy with other molecules (11).
- Bhat, R. et al. (2006) J. Leukoc. Biol. 79:417.
- de la Fuente, M.A. et al. (2001) Blood 97:3513.
- Sandrin, M.S. et al. (1992) J. Immunol. 149:1636.
- Romero, X. et al. (2004) Tissue Antigens 64:132.
- Hogarth, P.M. et al. (1980) Immunogenetics 11:65.
- Mathieson, B.J. et al. (1980) J. Immunol. 125:2127.
- Romero, X. et al. (2005) J. Immunol. 174:7033.
- Del Valle, J.M. et al. (2003) J. Biol. Chem. 278:17430.
- Martin, M. et al. (2005) J. Immunol. 174:5977.
- Sayos, J. et al. (2001) Blood 97:3867.
- Graham, D.B. et al. (2006) J. Immunol. 176:291.
Product Datasheets
Citation for Human CD229/SLAMF3 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
Authors: Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, Lajmi N, Zander AR, Marx AH, Luetkens T, Bokemeyer C, Kroger N
Haematologica, 2011-05-23;0(0):.
Species: Human
Sample Types: Cell Lysates, Whole Tissue
Applications: IHC-P, Western Blot
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CD229/SLAMF3 Antibody
Average Rating: 4 (Based on 1 Review)
Have you used Human CD229/SLAMF3 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
1:200 concentration used.
